What question did this study set out to answer?

This analysis aims to characterize BRAF fusion events in lung and colorectal cancer patients using DNA and RNA-based sequencing.

Abstract 5341: Real-world landscape of BRAF fusions in chinese patients with lung and colorectal cancers: Insights from 26,248 DNA-NGS and RNA-NGS tests.

View Full Paper

Ask AI

Bookmark

Authors

Analysis identifies BRAF fusion characteristics in lung and colorectal cancers, indicating the need for RNA-based sequencing.

This analysis aims to characterize BRAF fusion events in lung and colorectal cancer patients using DNA and RNA-based sequencing.
Conducted next-generation sequencing (NGS) on 26,248 patients, including separate analyses of 11,337 by DNA-NGS and 14,911 by RNA-NGS.
Systematically evaluated BRAF fusions, partner genes, and co-mutations.
Compared detection performance and fusion structure between DNA-NGS and RNA-NGS.
Identified 65 distinct BRAF fusions in 55 patients (0.43%), with the highest incidence in female patients (58.5%).
Most common fusion partner was IMMP2L (11.1%).
Co-mutations in 30 fusion-positive patients indicated a prevalence in lung cancer post-targeted therapy.
RNA-NGS detected only canonical 5′-3′ fusions while DNA-NGS exhibited non-canonical structures.
IMMP2L-BRAF fusion was exclusive to RNA-NGS, highlighting its advantages over DNA-NGS.

Wang et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

View Full Paper

Ask AI

Bookmark

Authors

Analysis identifies BRAF fusion characteristics in lung and colorectal cancers, indicating the need for RNA-based sequencing.

This analysis aims to characterize BRAF fusion events in lung and colorectal cancer patients using DNA and RNA-based sequencing.
Conducted next-generation sequencing (NGS) on 26,248 patients, including separate analyses of 11,337 by DNA-NGS and 14,911 by RNA-NGS.
Systematically evaluated BRAF fusions, partner genes, and co-mutations.
Compared detection performance and fusion structure between DNA-NGS and RNA-NGS.
Identified 65 distinct BRAF fusions in 55 patients (0.43%), with the highest incidence in female patients (58.5%).
Most common fusion partner was IMMP2L (11.1%).
Co-mutations in 30 fusion-positive patients indicated a prevalence in lung cancer post-targeted therapy.
RNA-NGS detected only canonical 5′-3′ fusions while DNA-NGS exhibited non-canonical structures.
IMMP2L-BRAF fusion was exclusive to RNA-NGS, highlighting its advantages over DNA-NGS.

Wang et al. (2026) studied this question.

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark